Monitoring of soluble HLA alloantigens and anti-HLA antibodies identifies heart allograft recipients at risk of transplant-associated coronary artery disease

Transplantation

Volumn 61, Issue 4, 1996, Pages 566-572

  Reed, Elaine F ^a   Hong, Bian ^a   Ho, Eric ^a   Harris, Paul E ^a   Weinberger, Judah ^a   Suciu Foca, Nicole ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; HLA ANTIBODY; HLA ANTIGEN;

ADULT; ANTIBODY DETECTION; ANTIGEN DETECTION; ARTICLE; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RISK ASSESSMENT;

ADOLESCENT; ADULT; ANTIBODIES; ANTIBODY FORMATION; CORONARY DISEASE; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HLA-A2 ANTIGEN; HUMANS; MALE; MIDDLE AGED; MONITORING, IMMUNOLOGIC; RISK FACTORS; SOLUBILITY;

EID: 0029914867     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199602270-00009     Document Type: Article

References (54)

1. Hosenpud JD, Novick RJ, Breen TJ, Daily OP. The registry of the International Society for Heart and Lung Transplantation: eleventh official report - 1994. J Heart Lung Transplant 1994; 13: 561.
2. Gao SZ, Schroeder JS, Alderman EL, et al. Prevalence of accelerated coronary artery disease in heart transplant survivors: comparison of cyclosporine and azathioprine regimens. Circulation 1989; 80 (suppl III): III-100.
3. Uretsky BF, Muralis S, Reddy PS, et al. Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone. Circulation 1987; 76: 827.
4. Johnson DE, Gao SZ, Schroeder JS, DeCampli WM, Billingham ME. The spectrum of coronary artery pathologic findings in human cardiac allografts. J Heart Transplant 1989; 8: 349.
5. Oguma S, Banner B, Zerbe T, Starzl T, Demetris AJ. Participation of dendritic cells in vascular lesions of chronic rejection of human allografts. Lancet 1988; 2: 933.
6. Hruban RH, Beschorner WE, Baumgartner WA, Austine SM, Ren H, Reitz BA. Accelerated arteriosclerosis in heart transplant recipients is associated with a T-lymphocyte-mediated endothelialitis. Am J Pathol 1990; 137: 871.
7. Usy CJ, Rose AG. Cardiac transplantation: aspects of the pathology. Pathol Annu 1983; 17: 147.
8. Gao SZ, Schroeder JS, Hunt S, Stinson EB. Retransplantation for severe accelerated coronary artery disease in heart transplant recipients. Am J Cardiol 1988; 62: 876.
9. Gao SZ, Schroeder JS, Alderman EL, et al. Clinical and laboratory correlates of accelerated coronary artery disease in the cardiac transplant patient. Circulation 1987; 76: 56.
10. Paul LC, Fellstrom B. Chronic vascular rejection of the heart and the kidney - have rational treatment options emerged? Transplantation 1992; 53: 1169.
11. Hayry P, Mennander A, Yilmaz S, et al. Towards understanding the pathophysiology of chronic rejection. Clinical Investigation 1992; 70: 780.
12. Tilney NL, Whitley WD, Diamond JR, Kupiec-Weglinski JW, Adams DH. Chronic rejection - an undefined conundrum. Transplantation 1991; 52: 389.
13. Salomon RN, Hughes CCW, Schoen FJ, et al. Human coronary transplantation associated arteriosclerosis: evidence for a chronic immune reaction to activated graft endothelial cells. Am J Pathol 1991; 138: 791.
14. Narrod J, Kormos R, Armitage J, Hardesty R, Ladowski J, Griffith B. Acute rejection and coronary artery disease in long-term survivors of heart transplantation. J Heart Transplant 1989; 8: 418.
15. Tesi RJ, Elkhammas EA, Henry ML, Davies EA, Salazar A, Ferguson RM. Acute rejection episodes: best predictor of long-term primary cadaveric renal transplant survival. Transplant Proc 1993; 25: 901.
16. Almond PS, Matas A, Gillingham K, et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993; 55: 752.
17. Hess HL, Hastilo A, Mohanakumar T, et al. Accelerated atherosclerosis in cardiac transplantation: role of cytotoxic B-cell antibodies and hyperlipidemia. Circulation 1983; 68: 94.
18. Fenoglio J, Ho E, Reed E, et al. Anti-HLA antibodies and heart allograft survival. Transplant Proc 1989; 21: 807.
19. Suciu-Foca N, Reed E, D'Agati VD, et al. Soluble HLA-antigens, anti-HLA antibodies and anti-idiotypic antibodies in the circulation of renal transplant recipients. Transplantation 1991; 51: 593.
20. Suciu-Foca N, Reed E, Marboe C, et al. Role of anti-HLA antibodies in heart transplantation. Transplantation 1991; 51: 716.
21. Suciu-Foca N, Ho E, King DW, et al. Soluble HLA and antiidiotypic antibodies in transplantation: modulation of anti-HLA antibodies by soluble HLA antigens from the graft and anti-idiotypic antibodies in renal and cardiac allograft recipients. Transplant Proc 1991; 23: 295.
22. Cherry R, Nielsen H, Reed E, et al. Vascular (humoral) rejection in cardiac allograft biopsies: relation to circulating anti-HLA antibodies. J Heart Lung Transplant 1992; 11: 24.
23. Reed E, Cohen DJ, Barr ML, et al. Effect of anti-HLA and anti-idiotypic antibodies on the long-term survival of heart and kidney allografts. Transplant Proc 1992; 24: 2494.
24. Reed E, Ho E, Cohen DJ, et al. Anti-idiotypic antibodies specific for HLA in heart and kidney allograft recipients. J Immunol Res 1993; 12: 1.
25. Barr M, Cohen DJ, Benvenisty AI, et al. Effect of anti-HLA antibodies on long-term survival of heart and kidney allografts. Transplant Proc 1993; 25: 262.
26. Benichou G, Takizawa PA, Olson CA, McMillan M, Sercarz EE. Donor major histocompatibility complex (MHC) peptides are presented by recipient MHC molecules during graft rejection. J Exp Med 1992; 175: 305.
27. Fangmann J, Dalchau R, Fabre JW. Rejection of skin allografts by indirect allorecognition of donor class I major histocompatibility complex peptides. J Exp Med 1992; 175: 152.
28. Liu Z, Sun YK, Xi YP, et al. Limited usage of TCR Vβ genes by allopeptide specific T cells. J Immunol 1993; 150: 3180.
29. Liu Z, Sun YK, Xi YP, et al. Contribution of direct and indirect recognition pathway to T cell alloreactivity. J Exp Med 1993; 177: 1643.
30. Sayegh MH, Watschinger B, Carpenter CB. Mechanisms of T cell recognition of alloantigen: the role of peptides. Transplantation 1994; 57: 1295.
31. Lee RS, Grusby MJ, Glimcher LH, Winn HJ, Auchincloss H. Indirect recognition by helper cells can induce donor-specific cytotoxic T lymphocytes in vivo. J Exp Med 1994; 179: 865.
32. Suciu-Foca N, Liu Z, Harris PE, et al. Indirect recognition of native HLA alloantigens and B-cell help. Transplant Proc 1995; 27: 455.
33. Dixon WJ, Brown MB, Engelman L, Jennrich RI. BMDP statistical software. University of California Press, 1990.
34. Cox DR, Oakes D. Analysis of survival data. London: Chapman and Hall, 1984.
35. Billingham ME, Cary NRB, Hammond ME, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: heart rejection study group. J Heart Transplantation 1990; 9: 587.
36. Gao S-Z, Alderman EL, Schroeder JS, Silverman JF, Hunt SA. Accelerated coronary vascular disease in the heart transplant patient: coronary angiographic findings. JACC 1988; 12: 334.
37. Yang SY, Milford E, Hammerling U, Dupont B. Description of the reference panel of B-lymphoblastoid cell lines for factors of the HLA system: the B-cell line panel designed for the Tenth International Histocompatibility Workshop. In: Dupont B, ed. Immunobiology of HLA. New York: Springer 1984: 11.
38. Colovai AI, Suciu-Foca N, Baiulescu GE, Harris PE. HLA class I self peptides isolated from a T cell leukemia reveal the allelespecific motif of HLA-B38. Tissue Antigens 1994; 44: 65.
39. Parham P, Brodsky FM. Partial purification and some properties of BB7.2: a cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28. Hum Immunol 1981; 3: 277.
40. Cook D. Long-term survival of kidney allografts. In: Terasaki PI, ed. Clinical transplantation. Los Angeles: UCLA Tissue Typing Laboratory, 1987: 277.
41. Opelz G. Effect of HLA matching in heart transplantation. Transplant Proc 1989; 21: 794.
42. Halloran PF, Schlaut J, Solez K, Srinivasa NS. The significance of the anti-class I response: II. Clinical and pathologic features of renal transplants with anti-class I-like antibody. Transplantation 1992; 5: 550.
43. O'Connel TX, Mobray JF. Arterial intimal thickening produced by alloantibody and xenoantibody. Transplantation 1973; 51: 262.
44. Hosenpud JD, Shipley GD, Morris TE, Hefeneider SH, Wagner CR. The modulation of human aortic endothelial cell ICAM-1 (CD-54) expression by serum containing high titers of anti-HLA antibodies. Transplantation 1993; 55: 405.
45. DeVito-Haynes LD, Jankowska-Gan E, Sollinger HW, Knechtle SJ, Burlingham WJ. Monitoring of kidney and simultaneous pancreas-kidney transplantation rejection by release of donor-specific, soluble HLA class I. Hum Immunol 1994; 40: 191.
46. Zavazava N, Bottcher H, Mueller-Ruchholtz W: Soluble MHC class I antigens (sHLA) and anti-HLA antibodies in heart and kidney allograft recipients. Tissue Antigens 1993; 42: 20.
47. Zavazava N, Leimenstoll G, Mueller-Ruchholtz W. Measurement of soluble MHC class I molecules in renal graft patients: a noninvasive allograft monitor. J Clin Lab Anal 1990; 4: 426.
48. Tilg H, Westhoff U, Vogel W, et al. Soluble HLA class I serum concentrations increase with transplant-related complications after liver transplantation. J Hepatol 1992; 14: 417.
49. Geissler EK, Wang J, Fechner JH Jr, et al. Immunity to MHC class I antigen after direct DNA transfer into skeletal muscle. J Immunol 1994; 152: 413.
50. Sherwood RA, Brent L, Rayfield LS. Presentation of alloantigens by host cells. Eur J Immunol 1986; 16: 569.
51. Dalchau R, Fangmann J, Fabre JW. Allorecognition of isolated, denatured chains of class I and class II major histocompatibility complex molecules: evidence for an important role for indirect allorecognition in transplantation. Eur J Immunol 1992; 22: 669.
52. Auchincloss HJ, Lee R, Shea S, Markowitz JS, Grusby MJ, Glimcher LH. The role of "indirect" recognition in initiating rejection of skin grafts from major histocompatibility complex class II-deficient mice. Proc Natl Acad Sci 1993; 90: 3373.
53. Simitsek PD, Campbell DG, Lanzavecchia A, Fairweather N, Watts C. Modulation of antigen processing by bound antibodies can boost or suppress class II major histocompatibility complex presentation of different T cell determinants. J Exp Med 1995; 181: 1957.
54. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and down regulated by tumor necrosis factor alpha. J Exp Med 1994; 179: 1109.